Articles

IABP, Datascope, Maquet, FDA recall

Datascope Corp./Maquet initiated a voluntary worldwide field correction of some of its intra-aortic balloon pumps (IABPs) due to a potential mechanical failure of the fan assembly associated with...

Percutaneous ventricular assist (pVAD) devices offer more hemodynamic support than the 40-year-old gold standard of intra-aortic balloon pumps (IABPs), but their cost and...

Since the 1970s, intra-aortic balloon pumps (IABPs) have been the gold standard of minimally invasive hemodynamic support, but more recently developed percutaneous ventricular assist devices (pVAD...

Two key news items in September made me think about the future direction of hemodynamic support, and that intra-aortic balloon pumps (IABP) will increasingly face a more serious...

FDA Intra-Aortic Balloon Pumps

November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to classify and regulate...

September 11, 2012 — Primary results from an ongoing trial by Maquet Cardiovascular using intra-aortic balloon pumps (IABP...

A transcatheter ventricular assist device performed better than intra-aortic balloon pumps (IABP), with a 21 percent reduction in major adverse events at 90 days.

The femoral artery approach for cardiac catheterizations has been used as the gold-standard in the United States, but there is growing interest in the transradial approach. One of the main...

The intra-aortic balloon pumps (IABPs) have been the gold standard for minimally invasive circulatory support for 40 years, but they were joined in recent years by percutaneously deployed...

Intra-aortic balloon pumps (IABPs), introduced in the 1970s, have been considered the standard of care for short-term circulatory support for more than two decades. However, there has been a...